Jaakko Lähteenmäki

Jaakko Lähteenmäki

Auto-generated profile, based on publicly available information

Jaakko Lähteenmäki

VTT Technical Research Centre of Finland Ltd. Espoo Finland

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2015 in Journal of Medical Internet Research
Verified
Journal Article
Open access
TKTuula Karhula
Tuula Karhula
AVAnna-Leena Vuorinen
Anna-Leena Vuorinen
KRKatja Rääpysjärvi
Katja Rääpysjärvi
MPMira Pakanen
Mira Pakanen
PIPentti Itkonen
Pentti Itkonen
NSNiilo Saranummi
Niilo Saranummi
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

11 December 2014 in Journal of Medical Internet Research
Verified
Journal Article
Open access
AVAnna-Leena Vuorinen
Anna-Leena Vuorinen
JLJuha Leppänen
Juha Leppänen
HKHannu Kaijanranta
Hannu Kaijanranta
MKMinna Kulju
Minna Kulju
Tiina HeliöTiina Heliö
Tiina Heliö
JLJaakko Lähteenmäki
Jaakko Lähteenmäki
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

27 May 2021 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
JLJaakko Lähteenmäki
Jaakko Lähteenmäki
AVAnna‐Leena Vuorinen
Anna‐Leena Vuorinen
JPJuha Pajula
Juha Pajula
KHKari Harno
Kari Harno
MLMika Lehto
Mika Lehto
MGMark van Gils
Mark van Gils
This study aimed to analyze associations between genetic variants and the occurrence of clinical outcomes in dabigatran, apixaban, and rivaroxaban users. This was a retrospective real‐world study linking genotype data of three Finnish biobanks with national register data on drug dispensations and healthcare encounters. We investigated several single‐nucleotide variants (SNVs) in the ABCG2, ABCB1, CES1, and CYP3A5 genes potentially associated with bleeding or thromboembolic events in direct oral anticoagulant (DOAC) users based on earlier research. We used Cox regression models to compare the incidence of clinical outcomes between carriers and noncarriers of the SNVs or haplotypes. In total, 1,806 patients on apixaban, dabigatran, or rivaroxaban were studied. The ABCB1 c.3435C>T (p.Ile1145=, rs1045642) SNV (hazard ratio (HR) 0.42, 95% confidence interval (CI), 0.18–0.98, P = 0.044) and 1236T‐2677T‐3435T (rs1128503‐rs2032582‐rs1045642) haplotype (HR 0.44, 95% CI, 0.20–0.95, P = 0.036) were associated with a reduced risk for thromboembolic outcomes, and the 1236C‐2677G‐3435C (HR 2.55, 95% CI, 1.03–6.36, P = 0.044) and 1236T‐2677G‐3435C (HR 5.88, 95% CI, 2.35–14.72, P < 0.001) haplotypes with an increased risk for thromboembolic outcomes in rivaroxaban users. The ABCB1 c.2482‐2236G>A (rs4148738) SNV associated with a lower risk for bleeding events (HR 0.37, 95% CI, 0.16–0.89, P = 0.025) in apixaban users. ABCB1 variants are potential factors affecting thromboembolic events in rivaroxaban users and bleeding events in apixaban users. Studies with larger numbers of patients are warranted for comprehensive assessment of the pharmacogenetic associations of DOACs and their relevance for clinical practice.

1 March 2021 in Clinical Epidemiology
Verified
Journal Article
Open access
PDF file
AVAnna-Leena Vuorinen
Anna-Leena Vuorinen
MLMika Lehto
Mika Lehto
MNMikko Niemi
Mikko Niemi
KHKari Harno
Kari Harno
JPJuha Pajula
Juha Pajula
JLJaakko Lähteenmäki
Jaakko Lähteenmäki
Purpose: To assess the association between VKORC1 and CYP2C9 variants and the incidence of adverse drug reactions in warfarin-treated patients in a real-world setting. Materials and Methods: This was a register-based cohort study (PreMed) linking data from Finnish biobanks, national health registries and patient records between January 1st 2007 and June 30th 2018. The inclusion criteria were: 1) ≥ 18 years of age, 2) CYP2C9 and VKORC1 genotype information available, 3) a diagnosis of a cardiovascular disease, 4) at least one warfarin purchase, 5) regular INR tests. Eligible individuals were divided into two warfarin sensitivity groups; normal responders, and sensitive and highly sensitive responders based on their VKORC1 and CYP2C9 genotypes. The incidences of clinical events were compared between the groups using Cox regression models. Results: The cohort consisted of 2508 participants (45% women, mean age of 69 years), of whom 65% were categorized as normal responders and 35% sensitive or highly sensitive responders. Compared to normal responders, sensitive and highly sensitive responders had fewer INR tests below 2 (median: 33.3% vs 43.8%, 95% CI: − 13.3%, − 10.0%) and more above 3 (median: 18.2% vs 6.7%, 95% Cl: 8.3%, 10.8%). The incidence (per 100 patient-years) of bleeding outcomes was 5.4 for normal responders and 5.6 for the sensitive and highly sensitive responder group (HR=1.03, 95% CI: 0.74, 1.44). The incidence of thromboembolic outcomes was 4.9 and 7.8, respectively (HR=1.48, 95% CI: 1.08, 2.03). Conclusion: In a real-world setting, genetically sensitive and highly sensitive responders to warfarin had more high INR tests and required a lower daily dose of warfarin than normal responders. However, the risk for bleeding events was not increased in sensitive and highly sensitive responders. Interestingly, the risk of thromboembolic outcomes was lower in normal responders compared to the sensitive and highly sensitive responders. Trial Registration: NCT04001166.

1 September 2009 in 2018 40th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC)
Verified
Conference Paper
Closed access
JLJaakko Lahteenmaki
Jaakko Lahteenmaki
JLJuha Leppanen
Juha Leppanen
HKHannu Kaijanranta
Hannu Kaijanranta
Personal health records (PHR's) and related services are emerging rapidly. Currently, most PHR's are isolated and do not communicate with other systems. Standards for interoperability exist, but they are oriented towards clinical applications. However, a substantial part of a typical PHR consists of non-clinical information such as a health diary. The present paper highlights the requirements related to exchanging non-clinical PHR information between services and shows how this information exchange can be accomplished. The approach utilizes a SOAP message for carrying the actual PHR content in a structure referred as health diary entry (HDE) document. The HDE document provides mechanisms to bind the contents to external vocabularies and ontologies to achieve semantic interoperability. The approach was successfully tested in the context of an occupational health pilot, in which data contents from several health and wellness applications were merged into a common database.

1 May 1999 in IEEE Transactions on Electromagnetic Compatibility
Verified
Journal Article
Closed access
WZWei Zhang
Wei Zhang
JLJ. Lahteenmaki
J. Lahteenmaki
PVP. Vainikainen
P. Vainikainen